Cat's Claw for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Cat's Claw for Health & Longevity

Created on 07/23/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Cat's claw bark extract shows modest support for less activity-related knee pain, and fewer tender joints as rheumatoid arthritis add-on care. Supportive cancer use may ease fatigue and quality of life without shrinking tumors. Stomach upset is common; interactions with major liver-metabolized drugs and immune stimulation are key safety issues. Extract chemistry aligned to the research lineage matters. (Full Review)

Protocol

Dose
60–350 mg/day extract
Product-specific; ~1 g bark 2–3× daily traditional; start low for GI tolerance
Chemotype
Extract matched to goal
POA / TOA-low for RA; water extract for DNA repair; freeze-dried U. guianensis for knee OA
Trial duration
4–24 weeks
4 weeks for joint pain; 8–24 weeks for slower immune endpoints; take with food
Time to effect
Knee OA pain
Within 1 week
Activity-related pain with freeze-dried U. guianensis
RA joint counts
Weeks to 6 months
Tender joints with POA extract as add-on
DNA repair markers
~8 weeks
Water extract (C-Med-100 lineage) in volunteers

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Planned surgery within about 2 weeks
  • Organ transplant recipients on immunosuppressants
  • Uncontrolled autoimmune disease without clinical supervision
  • Complex antiretroviral regimens without specialist clearance
  • Known allergy to Rubiaceae / Uncaria products
    •
Key Interactions
  • Antiretroviral protease inhibitors and other CYP3A4 substrates (atazanavir, ritonavir, saquinavir)
  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate, transplant corticosteroids)
  • Anticoagulants / antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel, high-dose aspirin)
  • Antihypertensives (ACE inhibitors, ARBs, calcium-channel blockers, beta-blockers)
  • Other immune-stimulating supplements (echinacea, astragalus, high-dose beta-glucans)
    •

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal upset; CYP3A4-mediated drug level increases
    •
  • Low: Immune stimulation and autoimmune flare potential; Headache, dizziness, or vomiting; Blood-pressure lowering tendency
    •
  • Speculative: Increased bleeding risk; Kidney injury or silica-related nephrolithiasis; Worsening of Parkinson disease motor symptoms; Pregnancy and fetal risk
    •

Monitoring

Marker Target Why
High-sensitivity CRP Often <1.0 mg/L (functional) Tracks systemic inflammatory tone for joint goals
ESR Age/sex-adjusted low-normal Complementary inflammatory marker in arthritis
CBC with differential Within age-appropriate norms Screens for unexpected hematologic change
Comprehensive metabolic panel (ALT, AST, creatinine, eGFR) Within lab norms; eGFR optimized for age Hepatic/renal safety baseline
Blood pressure (home average) Individualized; often <120/80 mmHg if tolerated Detects hypotensive additivity
INR / drug levels (if applicable) Per anticoagulant or antiretroviral targets Detects interaction-driven exposure changes

Cadence: Symptoms at 1–2 weeks (GI, BP, pain); labs at ~8–12 weeks if continuous use; every 6–12 months for long-term users on high-risk drugs, or sooner with regimen changes

Qualitative Assessment

  • Reduced activity-related joint pain or morning stiffness scores (user-reported 0–10 scale)
  • Improved function in preferred training or daily mobility tasks
  • Stable energy / fatigue scores if supportive-care goals apply
  • Absence of new GI intolerance, dizziness, or bruising
  • No destabilization of autoimmune or blood-pressure control
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.